14-12-2020 | SABCS 2020 | Conference coverage | Video

Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes

Roisin Connolly discusses the next steps following the negative results of the phase 3 ECOG-ACRIN E2112 trial of the HDAC inhibitor entinostat in combination with endocrine therapy in aromatase inhibitor-resistant patients with advanced breast cancer (2:43).

Read transcript

Image Credits

Connolly teaser image, ASCO 2021 teaser image/© rocketclips/ stock.adobe.com; dragana991 / Getty Images / iStock, ESMO breast-ASCO2021_image, ASCO Direct™ is an officially licensed program of the American Society of Clinical Oncology®. ASCO® and American Society of Clinical Oncology® are registered trademarks of the American Society of Clinical Oncology, Inc. Used with permission.

Medicine Matters Oncology

Entinostat addition fails to improve aromatase inhibitor-resistant breast cancer outcomes

2021 ASCO Annual Meeting coverage